| Nov 15 |
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
|
| Nov 12 |
Protara Therapeutics GAAP EPS of -$0.50 beats by $0.02
|
| Nov 12 |
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
|
| Nov 6 |
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
|
| Oct 21 |
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
|
| Sep 9 |
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
|
| Sep 9 |
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
|
| Sep 3 |
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 8 |
Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?
|
| Aug 6 |
Protara Therapeutics GAAP EPS of -$0.45
|
